Stratec SE (ETR:SBS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 218.81M |
| Revenue (ttm) | 250.86M |
| Net Income (ttm) | -242.00K |
| Shares Out | 12.16M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | 12.68 |
| Dividend | 0.60 (3.33%) |
| Ex-Dividend Date | Jun 30, 2025 |
| Volume | 10,246 |
| Average Volume | 10,128 |
| Open | 18.08 |
| Previous Close | 18.00 |
| Day's Range | 17.20 - 18.08 |
| 52-Week Range | 16.36 - 33.10 |
| Beta | 0.80 |
| RSI | 41.52 |
| Earnings Date | Apr 28, 2026 |
About Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1... [Read more]
Financial Performance
Financial StatementsNews
Stratec SE Earnings Call Transcript: Q4 2025
2025 saw stable revenue but lower margins amid geopolitical and supply chain challenges, with significant one-time charges impacting net income. Growth is expected to resume in 2026, driven by new product launches and efficiency gains, with margin recovery targeted by 2028.
EQS-AFR: STRATEC SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: STRATEC SE / Preliminary announcement on the disclosure of financial statements STRATEC SE: Preliminary announcement of the publication of financial rep...
Stratec SE Earnings Call Transcript: Q3 2025
Sales grew 2.5% year-over-year to EUR 175.6 million, with margin pressure from product mix and supply chain issues. Full-year guidance is for flat sales and lower margins, but Q4 is expected to improve. New partnerships, a syndicated loan, and market stabilization support a positive long-term outlook.
Stratec SE Earnings Call Transcript: Q2 2025
H1 2025 saw 5.2% sales growth, stable gross margin, but lower EBIT margin due to FX and one-offs. Full-year guidance is confirmed, with H2 expected to be back-end loaded and driven by Analyzer Systems sales acceleration. M&A and refinancing activities are ongoing.
Stratec SE Transcript: Health Care Conference
Recurring revenue from consumables and service parts now surpasses instrument sales, driven by a large installed base and post-COVID market dynamics. Growth is expected to resume in 2025 as replacement cycles and innovation in diagnostics drive demand, with a continued focus on M&A and cost discipline.
Stratec SE Earnings Call Transcript: Q4 2024
2024 saw improved margins and strong cash flow despite lower sales, driven by higher development and service revenues, cost discipline, and operational changes. Guidance for 2025 is cautious, with low to mid single-digit growth and a focus on inventory efficiency and cost control.
Stratec SE Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
A leading OEM in diagnostics, the company is navigating a post-COVID flat market with strong recurring revenues, robust cash flow, and a focus on smart consumables, AI, and operational efficiency. Market rebound is expected to drive growth and margin recovery.
Stratec SE Earnings Call Transcript: Q3 2024
Nine-month sales declined 6.1% year-over-year, with margins stabilized by efficiency measures. Management expects a strong Q4 to meet earnings guidance, despite ongoing market weakness in molecular diagnostics and high inventory levels.
Stratec SE Earnings Call Transcript: Q2 2024
H1 2024 saw improved margins and strong cash flow, with Q2 revenues up 6% and EPS up 220% year-over-year. Guidance for 2024 is confirmed, with a strong H2 expected, though risks remain around inventory and molecular segment recovery.